ProCE Banner Activity

CARTITUDE-4: Phase III Trial of Ciltacabtagene Autoleucel vs SoC for Lenalidomide-Refractory Multiple Myeloma

Conference Coverage
Slideset

Results from the phase III CARTITUDE-4 trial demonstrated improved PFS and ORR with cilta-cel vs SoC for patients with lenalidomide-refractory multiple myeloma, including after 1 previous line of therapy.

Released: June 12, 2023

Share

Provided by

Provided by Clinical Care Options, LLC.

ProCE Banner

Supporters

Supported by educational grants from AbbVie, Geron, Jazz Pharmaceuticals, Lilly, Merck Sharp & Dohme Corp., and Novartis.

AbbVie

Geron

Jazz Pharmaceuticals

Lilly

Merck Sharp & Dohme Corp.

Novartis